Answers are grounded in this paper and cite their sources.
Echinocandins are the preferred therapy for invasive infections due to Candida krusei. We present here a case of clinical failure involving C. krusei with a characteristic FKS1 hot spot mutation not previously reported in C. krusei that was isolated after 14 days of treatment. Anidulafungin MICs were elevated by ≥ 5 dilution steps above the clinical breakpoint but by only 1 step for a Candida albicans isolate harboring the corresponding mutation, suggesting a notable species-specific difference in the MIC increase conferred by this mutation.
No takes yet. Share an insight, caveat, or question.
Hare et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: